1. Home
  2. Vol 54, No 4 (2022)
  3. Rajabto

Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?

Wulyo Rajabto, Noviana Joenputri

Abstract


A 33-year-old male came to Policlinic of Hematology-Medical Oncology Dr. Cipto Mangunkusumo General Hospital for routine control of chronic myeloid leukemia (CML) treatment. He was treated with Imatinib Mesylate (IM) for two years. At the beginning of therapy, he showed good treatment response. However, after two years of treatment, he lost complete hematological response (CHR) occured and major molecular response (MMR) was not achieved. This demonstrated drug resistance even with good compliance. Evaluation of therapy through cytogenetic karyotype testing showed complex additional chromosomal abnormalities (ACA) in addition to the Philadelphia chromosome (Ph). Tyrosine kinase inhibitor (TKI) therapy in this type of patients should be replaced with other alternative TKIs. A mutation profiling test is needed to determine alternative TKI. Monitoring in the treatment of CML patients is very important. The presence of ACA indicates disease progression and poor prognosis. Time to change therapy in CML patients must be done appropriately based on the results of hematological, molecular, and cytogenetic testing.


Keywords


chronic myeloid leukemia; additional chromosomal abnormalities; drug resistance

References


Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-50.

Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31(3):593.

Au WY, Caguoia PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.

Rajabto W, Reksodiputro AH, Tadjoedin H, Harimurti K. Hubungan gambaran klinis dan laboratorium hematologis antara leukemia granulositik kronik Ph(+)/BCR-ABL(+) dengan bentuk kelainan Ph/BCR-ABL lainnya. Jurnal Penyakit Dalam Indonesia. 2018;5(1):11-6.

Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment, and follow up. Ann Oncol. 2017;28 (Suppl 4):iv41-iv51.

Radich JP, Deininger M, Abboud CN, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Nat Comprehensive Cancer Network. 2018;16(9):1108-35.

Jabbour E, Kantarjian H. Chronic myeloid leukemia. Chronic myeloid leukemia: 2018 update on diagnosis, therapy, and monitoring. Am J Hematol. 2018;93:442-59.

Crisan AM, Coriu D, Arion C, Colita A, Jardan C. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with TKI in CML. J Med and Life. 2015;8(4):502-8.

Chandran RK, Geetha N, Sakthivel KM, et al. Impact of additional chromosome abberation on the disease progression of chronic myeloid leukemia. Front. Oncol. 2019;9(88):1-12.

Dorfman LE, Floriani MA, Oliveira TMRDR, et al. The role of cytogenetics and molecular biology in the diagnosis, treatment, and monitoring of patients with chronic myeloid leukemia. J Pras Pathol Med Lab. 2018;54(2);83-91.

Shah J. The importance of hematologic, cytogenetic, and molecular testing and mutational analysis in chronic myeloid leukemia. JCSO. 2014;121:179-87.

Vigil CE, Griffiths EA, Wang ESWetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Rev. 2011;25(3):139-46.

Hughes T, White D. Which TKI? AN embarrassment of riches for chronic myeloid leukemia patients. Hematology. 2013:168-75.

Bitencourt R, Zalcberg I, Louro ID. Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2011;33(6):470-5.

Bhamidipati P, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther adv Hematol 2013;4(2):103-17.


Full Text: PDF

Refbacks

  • There are currently no refbacks.